Aeterna Zentaris Inc. (NASDAQ:AEZS) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a note issued to investors on Tuesday.

According to Zacks, “AEterna Zentaris Inc. is a biopharmaceutical company focused on endocrine therapy and oncology. Its lead endocrinology program is a Phase 3 trial in benign prostatic hyperplasia (BPH) with cetrorelix, an LHRH antagonist already marketed for in vitro fertilization under the brand name Cetrotide. The lead oncology program is a Phase 2 trial in endometrial and ovarian cancer with AEZS-108, a targeted cytotoxic peptide conjugate. Other lead compounds include ozarelix for BPH and prostate cancer as well as perifosine for multiple cancers. “

A number of other analysts also recently issued reports on the stock. Canaccord Genuity restated a “buy” rating and set a $9.00 price objective on shares of Aeterna Zentaris in a report on Tuesday, August 23rd. Maxim Group restated a “buy” rating and set a $11.00 price objective on shares of Aeterna Zentaris in a report on Saturday, August 13th. Finally, HC Wainwright restated a “buy” rating on shares of Aeterna Zentaris in a report on Thursday, August 11th.

Shares of Aeterna Zentaris (NASDAQ:AEZS) opened at 3.80 on Tuesday. Aeterna Zentaris has a one year low of $2.60 and a one year high of $15.70. The stock’s 50 day moving average is $3.51 and its 200-day moving average is $3.54. The company’s market cap is $37.77 million.

Aeterna Zentaris (NASDAQ:AEZS) last posted its quarterly earnings data on Tuesday, August 9th. The biopharmaceutical company reported ($0.71) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.82) by $0.11. Aeterna Zentaris had a negative net margin of 5,871.45% and a negative return on equity of 241.78%. Equities research analysts forecast that Aeterna Zentaris will post ($2.61) earnings per share for the current year.

An institutional investor recently raised its position in Aeterna Zentaris stock. Renaissance Technologies LLC raised its stake in Aeterna Zentaris Inc. (NASDAQ:AEZS) by 5.9% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 516,833 shares of the biopharmaceutical company’s stock after buying an additional 29,000 shares during the period. Renaissance Technologies LLC owned 8.17% of Aeterna Zentaris worth $1,716,000 at the end of the most recent reporting period. Institutional investors own 8.28% of the company’s stock.

Aeterna Zentaris Company Profile

Aeterna Zentaris Inc is a specialty biopharmaceutical company engaged in developing and commercializing treatments in oncology, endocrinology and women’s health. The Company operates through the biopharmaceutical segment. The Company is engaged in drug development activities and in the promotion of products for others.

5 Day Chart for NASDAQ:AEZS

Get a free copy of the Zacks research report on Aeterna Zentaris (AEZS)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for Aeterna Zentaris Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aeterna Zentaris Inc. and related companies with's FREE daily email newsletter.